Am J Cancer Res 2024;14(10):5114-5115
www.ajcr.us /ISSN:2156-6976/ajcr0160294

Erratum
Targeting NF-κB/AP-2β signaling to enhance antitumor activity of cisplatin by melatonin in hepatocellular carcinoma cells: Am J Cancer Res. 2017; 7(1): 13-27

Jiaojiao Hao[1*], Zhenglin Li[1*], Changlin Zhang[2], Wendan Yu[1], Zhipeng Tang[1], Yixin Li[2], Xu Feng[1], Yue Gao[1], Quentin Liu[1,2], Wenlin Huang[2,3], Wei Guo[1], Wuguo Deng[2,3]

[1]Institute of Cancer Stem Cell, Dalian Medical University, Dalian, Liaoning, China; [2]Sun Yat-sen University Cancer Centre; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Guangzhou, Guangdong, China; [3]State Key Laboratory of Targeted Drug for Tumors of Guangdong Province, Guangzhou Double Bioproduct Inc., Guangzhou, Guangdong, China. [*]Equal contributors and co-first authors.

Received September 3, 2024; Accepted October 9, 2024; Epub October 25, 2024; Published October 30, 2024

In the submitted revised version, an incorrect file for **Figure 2B** was inadvertently uploaded. We apologize for any confusion this may have caused. The corrected **Figure 2B** is presented below.

Address correspondence to: Wei Guo, Institute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, Liaoning, China. E-mail: wei1015@dmu.edu.cn; Wuguo Deng, Sun Yat-sen University Cancer Center, Guangzhou 510060, Guangdong, China. E-mail: dengwg@sysucc.org.cn

https://doi.org/10.62347/SUKI5933



Figure 2. Melatonin enhanced cisplatin-mediated inhibition of colony formation and cell migration in hepatocellular carcinoma cells. A. Clone formation in BEL-7402 cells and SNU-449 cells treated with cisplatin (CDDP) (2.5 μM) and melatonin (MT) (1.0 mM) for 48 h were observed. B. Cell migration was analyzed by a scratch assay. BEL-7402 cells and SNU-449 cells were grown to full confluency. The cell monolayers were wounded with a sterile pipette tip, and washed with medium to remove detached cells from the plates. Then the cells were left either untreated or treated with cisplatin (CDDP) (2.5 μM) or melatonin (MT) (1.0 mM). After 36 h, the wound gap was observed and photographed. *P < 0.05, significant differences between the CDDP+MT-treated groups and the CDDP-treated groups.